Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis [6]

American Journal of Hematology

Volumn 81, Issue 6, 2006, Pages 474-

  Ozdemir, Evren ^a   Koc, Yener ^a   Kansu, Emin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; BLOOD CELL COUNT; BLOOD SMEAR; CASE REPORT; CHRONIC KIDNEY FAILURE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG ELIMINATION; DRUG EXCRETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMODIALYSIS; HUMAN; LETTER; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KIDNEY FAILURE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33646868858     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20620     Document Type: Letter

References (5)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
2. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase 1 trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
3. Bauer S, Hagen V, Pielken HJ, et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 2002;13:847-849.
4. Pappas P, Karavasilis V, Briasoulis E, et al. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005;56:358-360.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.